

Statistics of Haematological Malignancies in 2023
2023年血液惡性腫瘤統計數據摘要

The Hong Kong Cancer Registry has updated its guidelines for cancer reporting for cases diagnosed from 2020. The International Classification of Diseases for Oncology, 3rd edition, 2nd revision (ICD-O-3.2) and WHO Classification of Haematologic and Lymphoid Tissues, 4th ed, 2017 (which is based on ICD-O-3.2) are the main sources for coding and reporting Haematological Malignancies presented in this report. Several diseases such as lymphomas, leukaemias, myelomas, myelodysplastic syndromes and myeloproliferative diseases are now tabulated as Haematological Malignancies.

中心已根據國際腫瘤疾病分類第3.2版 (ICD-O-3.2) 對於自2020年起確診的惡性疾病實施新的報告標準。血液惡性腫瘤分類主要根據世界衛生組織2017年出版關於血液及淋巴組織的期刊來進行，包括淋巴瘤、白血病、骨髓瘤、骨髓增生異常綜合症和骨髓增生性疾病等。

Table 1. Incidence of Haematological Malignancies in 2023

列表一 2023年血液及淋巴惡性疾病發病數字

	Male 男性	Female 女性
Number of cases registered 登記個案數目	1,531	1,251
Median age (years) 年齡中位數 (歲)	66	65
Crude rate 粗發病率	44.6	30.5
Age-standardised rate [ASR] ¹ 年齡標準化比率 ¹	22.6	17.4
Lifetime risk before age 75 一生累積風險 (0-74歲)	1 in 43	1 in 59

Table 2. New Cases of Haematological Malignancies by Age Group in 2023

列表二 2023年血液及淋巴惡性疾病新症數字

Category類別	Age group (years) 年齡組別 (歲)					Total 總計	Crude rate 粗發病率	ASR 年齡標準化 比率 ¹
	0-19	20-44	45-64	65-74	75+			
Myeloproliferative neoplasms 骨髓增生性腫瘤	5	54	153	103	60	375	5.0	2.6
Mastocytosis 肥大細胞增生症	0	0	0	0	0	0	0	0
Myeloid/Lymphoid neoplasms with esoinophils and gene rearrangement 伴有嗜酸性粒細胞增多和基因重排的髓系/淋巴系腫瘤	0	1	0	0	0	1	0.01	0.01
Myelodysplastic/Myeloproliferative neoplasms 骨髓增生異常/增生性腫瘤	0	1	12	20	26	59	0.8	0.3
Myelodysplastic syndromes 骨髓增生異常綜合症	0	2	31	41	76	150	2.0	0.7
Acute myeloid leukaemia and related precursor neoplasms 急性髓細胞白血病及與其有關之前驅腫瘤	12	33	101	89	108	343	4.6	2.4
Acute leukaemias of Ambiguous Lineage 譜系未定的急性白血病	0	0	3	1	4	8	0.1	0.04
Precursor lymphoid neoplasms 前驅淋巴性腫瘤	42	29	27	14	5	117	1.6	2.5
Mature B-cell neoplasms 成熟B細胞淋巴瘤	11	100	487	514	379	1,491	19.8	9.0
Mature T- and NK-cell neoplasms 成熟T細胞和NK細胞淋巴瘤	2	14	48	38	33	135	1.8	0.9
Hodgkin lymphoma 霍奇金淋巴瘤	12	34	15	10	8	79	1.0	1.1
Histiocytic and dendritic cell neoplasms 組織細胞和樹突細胞腫瘤	3	1	8	3	1	16	0.2	0.2
Malignant lymphoma, NOS 其他惡性淋巴瘤	0	0	2	2	3	7	0.1	0.03
Leukaemia, other and NOS 其他白血病	0	0	0	1	0	1	0.01	0.005
Total總計	87	269	887	836	703	2,782	36.9	19.8

¹ Age-standardised rates (ASR) are age-adjusted to the World Standard Population of Segi (1960) and expressed per 100,000 population. Comparisons with these rates from other sources are valid only under the same standard population for calculations.

年齡標準化比率是根據 Segi (1960) 世界標準人口並以每十萬人口計算。用於進行比較不同族群之間的疾病率時，需以同一標準人口為基準計算才有意義。

Figure 1. Relative Frequency of Haematological Malignancy in 2023

圖表一 2023年血液及淋巴惡性疾病類別分布




Figure 2. Age-specific Incidence Rate for Haematological Malignancy in 2023

圖表二 2023年按年齡組別分布的血液及淋巴惡性疾病發病率

